JPMorgan lowered the firm’s price target on Progyny to $49 from $57 and keeps an Overweight rating on the shares. The analyst assumes the company’s utilization patterns remain consistent going forward. The firm updated its model to account for Progyny’s new federal government plan which added 300,000 lives. It expects 20% revenue growth in 2024, and 21% EBITDA growth.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PGNY:
- Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Progyny price target lowered to $45 from $50 at KeyBanc
- Progyny sees FY23 revenue $1.087B-$1.1B, consensus 1.08B
- Progyny reports Q3 EPS 16c, consensus 12c
- Progyny, Inc. Announces Third Quarter 2023 Results